Assessing adherence to oral chemotherapy using different measurement methods: Lessons learned from capecitabine

Journal of Oncology Pharmacy Practice

Volumn 20, Issue 4, 2014, Pages 249-256

  Walter, Thomas ^a,b   Wang, Lisa ^a   Chuk, Karen ^a   Ng, Pamela ^a   Tannock, Ian F ^a,c   Krzyzanowska, Monika K ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adherence; Capecitabine; Microelectronic monitoring; Oral anticancer agents

Indexed keywords

CAPECITABINE;

ADULT; AGED; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PILOT STUDY; PROSPECTIVE STUDY;

ADMINISTRATION, ORAL; ADULT; AGED; CAPECITABINE; COHORT STUDIES; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 84905639424     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155213501100     Document Type: Article

References (24)

1. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104
2. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA 2012; 307: 1265-1272
3. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115
4. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28: 2381-2388
5. Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on longterm therapy. Blood 2011; 117: 3733-3736
6. Ruddy K, Mayer E and Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009; 59: 56-66
7. Osterberg L and Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497
8. Waterhouse DM, Calzone KA, Mele C, et al. Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993; 11: 1189-1197
9. Partridge AH, Archer L, Kornblith AB, et al. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: Adherence companion study 60104. J Clin Oncol 2010; 28: 2418-2422
10. Love RR. Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst 1990; 82: 18-21
11. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen- receptor-positive tumors. N Engl J Med 1989; 320: 479-484
12. Partridge AH, Avorn J, Wang PS, et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94: 652-661
13. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273-3277
14. Winterhalder R, Hoesli P, Delmore G, et al. Self-reported compliance with capecitabine: Findings from a prospective cohort analysis. Oncology 2011; 80: 29-33
15. Bhattacharya D, Easthall C, Willoughby KA, et al. Capecitabine non-adherence: Exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract 2012; 18: 333-342
16. Timmers L, Swart EL, Boons CC, et al. The use of capecitabine in daily practice: A study on adherence and patients' experiences. Patient Prefer Adherence 2012; 6: 741-748
17. Leventhal H, Nerenz DR, Leventhal EA, et al. The behavioral dynamics of clinical trials. Prev Med 1991; 20: 132-146
18. Ruddy KJ, Pitcher BN, Archer LE, et al. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Ann Oncol 2012; 23: 3075-3081
19. Thivat E, Van Praagh I, Belliere A, et al. Adherence with oral oncologic treatment in cancer patients: Interest of an adherence score of all dosing errors. Oncology 2013; 84: 67-74
20. Lee CR, Nicholson PW, Souhami RL, et al. Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol 1992; 10: 1007-1013
21. Macintosh PW, Pond GR, Pond BJ, et al. A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes. Eur J Cancer Care (Engl) 2007; 16: 380-386
22. Lee CR, Nicholson PW, Souhami RL, et al. Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer 1993; 67: 630-634
23. Lebovits AH, Strain JJ, Schleifer SJ, et al. Patient noncompliance with self-administered chemotherapy. Cancer 1990; 65: 17-22
24. Levine AM, Richardson JL, Marks G, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987; 5: 1469-1476